<!DOCTYPE html>
        
<html lang="zh-Hant-TW">
		<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<meta name="generator" content="Hugo 0.65.3" />
	
	<link rel="icon" href="http://www.4stack.pro/img/logo.png">
	
	<title>美國大學研究 NHC 能對抗多種冠狀病毒！連能抵擋 remdesivir 抗藥性病毒也消滅 | Rumor Theory</title>
	
	

	<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="美國大學研究 NHC 能對抗多種冠狀病毒！連能抵擋 remdesivir 抗藥性病毒也消滅"/>
<meta name="twitter:description" content="研究發現 NHC 藥物對冠狀病毒有著致命的變異催化性。對多種冠狀病毒"/>

	<meta property="og:title" content="美國大學研究 NHC 能對抗多種冠狀病毒！連能抵擋 remdesivir 抗藥性病毒也消滅" />
<meta property="og:description" content="研究發現 NHC 藥物對冠狀病毒有著致命的變異催化性。對多種冠狀病毒" />
<meta property="og:type" content="article" />
<meta property="og:url" content="http://www.4stack.pro/news/american-research-university-can-nhc-against-a-variety-of-coronavirus-even-drug-resistant-virus-can-also-destr/" />
<meta property="article:published_time" content="2020-04-10T03:42:53+08:00" />
<meta property="article:modified_time" content="2020-04-10T03:42:53+08:00" />




    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/latest/css/font-awesome.min.css" />
    
    
    <link href="http://www.4stack.pro/css/bootstrap.min.css" rel="stylesheet" />
    <link href="http://www.4stack.pro/css/demo.css" rel="stylesheet" />
    <link href="http://www.4stack.pro/css/navbar-top-fixed.css" rel="stylesheet" />



 





  
  <meta property="og:image" content="http://www.4stack.pro/news/american-research-university-can-nhc-against-a-variety-of-coronavirus-even-drug-resistant-virus-can-also-destr/cover.jpg" />





 



	<meta name="keywords" content=""/>
	<meta name="description" content=""/>


	<link href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous">
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.0.13/css/all.css" integrity="sha384-DNOHZ68U8hZfKXOrtjWvjxusGo9WQnrNx2sqG0tfsghAvtVlRW3tvkXWZh58N9jp"
	 crossorigin="anonymous">
	<link href="https://fonts.googleapis.com/css?family=Righteous%7CMerriweather:300,300i,400,400i,700,700i" rel="stylesheet">
	<link href="http://www.4stack.pro/css/medium.css" rel="stylesheet">
	<link href="http://www.4stack.pro/css/additional.css" rel="stylesheet">
	<script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>

<script data-ad-client="ca-pub-2730293094729387" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="application/ld+json">


{
  "@context": "https://schema.org",
  "@type": "Organization",
  "name": "Rumor Theory",
  "url": "http://www.4stack.pro/",
  "sameAs": [
    "https://www.facebook.com/m.media168"
  ]
}

</script>
</head>
<body>


 <nav class="navbar navbar-expand-md navbar-dark fixed-top bg-dark">
      <a class="navbar-brand" href="http://www.4stack.pro/">M media</a>
	  &nbsp; <div id="navbar_top" name="navbar_top"></div>
      <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
        <span class="navbar-toggler-icon"></span>
      </button>

      <div class="collapse navbar-collapse" id="navbarCollapse">
        <ul class="navbar-nav mr-auto" id="mymenu">
        </ul>
      </div>
    </nav>






        <div class="site-content">   
            <div class="container">
<div class="main-content">
        
        <div class="container">
            <div class="row">
                
                <div class="col-md-2 pl-0"><div class="share sticky-top sticky-top-offset">
    <p>Share</p>
    <ul>
        <li class="ml-1 mr-1">
        <a target="_blank" href="https://twitter.com/intent/tweet?text=%e7%be%8e%e5%9c%8b%e5%a4%a7%e5%ad%b8%e7%a0%94%e7%a9%b6%20NHC%20%e8%83%bd%e5%b0%8d%e6%8a%97%e5%a4%9a%e7%a8%ae%e5%86%a0%e7%8b%80%e7%97%85%e6%af%92%ef%bc%81%e9%80%a3%e8%83%bd%e6%8a%b5%e6%93%8b%20remdesivir%20%e6%8a%97%e8%97%a5%e6%80%a7%e7%97%85%e6%af%92%e4%b9%9f%e6%b6%88%e6%bb%85&url=http%3a%2f%2fwww.4stack.pro%2fnews%2famerican-research-university-can-nhc-against-a-variety-of-coronavirus-even-drug-resistant-virus-can-also-destr%2f" onclick="window.open(this.href, 'twitter-share', 'width=550,height=435');return false;">
        <i class="fab fa-twitter"></i>
        </a>
        </li>
        
        <li class="ml-1 mr-1">
        <a target="_blank" href="https://facebook.com/sharer.php?u=http%3a%2f%2fwww.4stack.pro%2fnews%2famerican-research-university-can-nhc-against-a-variety-of-coronavirus-even-drug-resistant-virus-can-also-destr%2f" onclick="window.open(this.href, 'facebook-share', 'width=550,height=435');return false;">
        <i class="fab fa-facebook-f"></i>
        </a>
        </li>

        <li class="ml-1 mr-1">
        <a target="_blank" href="https://www.xing.com/spi/shares/new?url=http%3a%2f%2fwww.4stack.pro%2fnews%2famerican-research-university-can-nhc-against-a-variety-of-coronavirus-even-drug-resistant-virus-can-also-destr%2f" onclick="window.open(this.href, 'xing-share', 'width=550,height=435');return false;">
        <i class="fab fa-xing"></i>
        </a>
        </li>        
    </ul>

    
</div>
</div>
                                
                <div class="col-md-9 flex-first flex-md-unordered">
                    <div class="mainheading">
                        	
                                                
                        
                        <h3 class="posttitle">美國大學研究 NHC 能對抗多種冠狀病毒！連能抵擋 remdesivir 抗藥性病毒也消滅</h3> 
                    </div>

                    
                    
                    
                    

                    
                    <div class="article-post">

						 <p><img src="https://geneonline.news/wp-content/uploads/2020/04/140517804_l.jpg" alt="img">
研究發現 NHC 藥物對冠狀病毒有著致命的變異催化性。對多種冠狀病毒適用，並且有口服藥效性，讓它成為對抗 SARS-CoV-2 的有力分子候選，也可作為未來人畜共通冠狀病毒藥物的開發選項之一。</p>
<p>冠狀病毒是 RNA 病毒的一種，常在不同物種間交互傳播，形成各種變異株，甚而引起人類流行病。最近的大傳染病爆發就是來自 SARS-CoV-2 病毒的傳播。日前美國科學家發現核糖核酸相似物 β-D-N4-hydroxycytidine (NHC, EIDD-1931)，能夠廣泛性地對抗冠狀病毒系列如 SARS-CoV-2、MERS-CoV，SARS-CoV，以及人畜共通 2b，2c Bat-CoVs，甚至在對 remdesivir 有抗藥性的基因變異個體中也能觀察到療效。在感染 SARS-CoV 或是 MERS-CoV 老鼠模型上做的實驗可以觀察到，不管是預防性的或治療性的給予 EIDD-2801 ——另一支口服 NHC 前驅藥物 (β-D-N4-hydroxycytidine-5′-isopropyl ester) 都能看到肺部功能的改善，病毒量減少以及體重減輕症狀的改善。並且實驗中觀察抗病毒作用是來自於病毒本身RNA的變異堆積，而沒有影響宿主 RNA，證明了 NHC 藥物對冠狀病毒有著致命的變異催化性。EIDD-2801 對多種冠狀病毒適用，並且有口服藥效性，讓它成為對抗 SARS-CoV-2 的有力分子候選，也可作為未來人畜共通冠狀病毒藥物的開發選項之一。</p>
<p>冠狀病毒的人畜共通性讓危險度大增</p>
<p>頻發在哺乳類及禽類中來回傳播的冠狀病毒科，共有四種屬。從 2002 迄今已經有三個大規模流行病造成災禍的冠狀病毒出現，2020 年肆虐的 SARS-CoV-2 和其他前者相通，能夠引發急性肺衰竭、並讓肺部症狀短時間惡化、預後不佳。由於多源於人畜共通傳染，這個致病機轉當然不僅限在人類，中國廣東省近來也出現豬隻身上感染來自蝙蝠的冠狀病毒 swine acute diarrhea syndrome CoV (SADS-CoV)，造成約 20,000 豬隻的死亡。而更加令人提心吊膽的是，許多循環在蝙蝠族群中感染傳播，與 SARS 相仿的第 2 屬病毒，可以直接利用人類細胞受體並在人類肺細胞株中快速傳播無需適應突變期。這些致傳染病型病毒的存在，說明了抗冠狀病毒分子篩選的重要性，加上人畜共通性質，更讓危機無所不在，能夠抗多樣性冠狀病毒的廣泛性抗病毒試劑相當具有開發價值。</p>
<p>新分子 NHC 可以藉由累積突變毒殺冠狀病毒</p>
<p>β-D-N4-hydroxycytidine 是一項生物可利用型核糖核苷酸相似物，能有效抑制許多分屬不同類型的 RNA 病毒，如伊波拉病毒 (Ebola)，流感病毒 (Influenza)，冠狀病毒 (Coronavirus)，委內瑞拉馬腦炎病毒 (Venezuelan equine encephalitis virus) 等。從委內瑞拉馬腦炎病毒的作用機制觀察，NHC 主要透過增加病毒核酸的惡性點置換突變，來造成病毒消亡。使用感染 MERS-CoV 的肺部上皮細胞株進行投藥，可以看到 NHC 表現出半最大抑制濃度 (IC50) 為 0.15 μM，並且相同濃度投放在未感染的一般肺上皮細胞，並沒有展現細胞毒性。而使用 NHC 對純化後的SARS-CoV-2 進行測試的治療指數 (therapeutic index) 大於 100。在非洲綠猴腎細胞株 Vero cell line 表現新型冠狀病毒，並以 NHC 治療的 IC50 為 0.3 μM，以實驗感染肺部上皮細胞並投藥的結果，所測得的 IC50 則是 0.08 μM，以定量 RT-PCR 做細胞培養基上清液體的測試也可以看到隨著投藥量的增加，病毒濃度隨著減少，最大抑制濃度約為 0.09 μM。由此可證，NHC 分子對兩種基因序列不完全相同的冠狀病毒，都具有抑制並減少的功效。使用組織中取得之初級人類氣管上皮細胞，來驗證是否在形與細胞組織較為複雜的人類氣管細胞中，NHC分子能夠一樣表現抗病毒效用。在 MERS-CoV、SARS-CoV 以及 SARS-CoV-2 感染的初級人類氣管上皮細胞培養中，利用基因偵測 (qPCR)，都能觀察到 NHC 不僅不會造成正常細胞毒性，更能夠在一定劑量之下就使病毒量有效減少。</p>
<p>NHC 能夠消滅 remdesivir 抗藥性冠狀病毒</p>
<p>冠狀病毒根據基因能夠分為 4 個亞組，而其中只有 alpha、beta 亞組的病毒能夠感染人類。其中一個關鍵的相似點在於 RNA-dependent RNA polymerase (RdRp, nsp12) 蛋白，如 SARS-CoV 與 SARS-CoV-2 的 RdRp 基因相似度高達 99.1% 氨基酸序列相似度則有 96%。利用樹狀圖分析冠狀病毒家族的 RdRp 親緣性，可以發現RdRp 的核心分子與主要結構模體在冠狀病毒家族中十分保守相似。並且此研究團隊先前就發表，利用病毒模型監測，發現對 remdesivir 有抗藥性的冠狀病毒，主要由於RdRp 的 F480L 或 V557L 氨基酸點突變。在本實驗中，研究人員也進一步嘗試對抗 remdesivir 的突變病毒施用 NHC，發現這兩個突變單一或共同出現，都會增加病毒對 NHC 的敏感度。綜合前述抗病毒能力測試，加上對 remdesivir 抗藥性病毒株的有效性，NHC 可以作為與 remdesivir 互相搭配互補的藥物選項，用以治療多種冠狀病毒的感染。並且研究團隊進一步篩選 3 組能夠傳染人類的蝙蝠冠狀病毒株感染人類氣管上皮細胞，在加入 NHC 後也都成功降低了病毒量，展現了在親緣性較遠的 RdRp 表現病毒中，NHC 依然具有抗病毒效能。</p>
<p>NHC 作用機制——增加病毒突變率</p>
<p>近一步探究兩種藥物對抗冠狀病毒的機制，研究團隊利用病毒株感染人類氣管上皮細胞進行深度次世代基因定序。根據先前研究已知 remdesivir 的主要作用為促使RNA 鏈終止，減少病毒複製。而在定序結果中，則發現NHC處理的細胞組別有高定序錯誤率，顯示基因高度變異，觀察變異序列可以知道 NHC 藉由增加 A:G、C:U 置換率造成病毒 RNA 轉錄錯誤，近一步終止病毒複製及存活。將NHC的口服前驅藥物施用在老鼠組別中，可以發現 NHC 前驅藥物 EIDD-2801 可以改善 SARS-CoV以及 MERS-CoV 感染小鼠的症狀，包含體重減輕、肺出血以及降低肺部的病毒量。最後實驗團隊檢測在感染後的不同時間點進行投藥，觀察 EIDD-2801 對感染症狀的改善程度，發現對於 SARS-CoV 感染所造成的急性肺損傷改善的程度會由感染直到投藥的時間長度決定，在感染後一天內治療效果較佳，而 MERS-CoV 則是在感染前 2 小時，或感染後 12 小時內投藥，才能得到較好的抗病毒效果。</p>
<p>完整的研究由美國北卡羅來納大學研究團隊於今年 4 月份發表在 Science Translational Medicine 期刊上，能夠廣泛應用在多種不同冠狀病毒的特性，讓NHC 的醫療化價值更高，希望相關產業化行動能夠盡快進行，善用科學研究來降低疫病蔓延所造成的高社會與醫療成本。</p>
<p>延伸閱讀：抗新冠肺炎雙藥齊下！美 FDA 擬推抗瘧疾藥物和恢復期血漿</p>
<p>參考資料：</p>
<p><a href="https://stm.sciencemag.org/content/early/2020/04/03/scitranslmed.abb5883?utm_campaign=SciMag&amp;utm_source=JHubbard&amp;utm_medium=Facebook">https://stm.sciencemag.org/content/early/2020/04/03/scitranslmed.abb5883?utm_campaign=SciMag&amp;utm_source=JHubbard&amp;utm_medium=Facebook</a> <a href="http://eidd.emory.edu/programs/index.html">http://eidd.emory.edu/programs/index.html</a> <a href="https://sph.unc.edu/sph-news/a-new-antiviral-drug-heading-into-clinical-trials-offers-hope-for-covid-19-treatment-in-part-because-it-can-be-taken-as-a-pill/">https://sph.unc.edu/sph-news/a-new-antiviral-drug-heading-into-clinical-trials-offers-hope-for-covid-19-treatment-in-part-because-it-can-be-taken-as-a-pill/</a></p>
<p>©www.geneonline.news. All rights reserved. 基因線上版權所有 未經授權不得轉載。合作請聯繫：[email protected]


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>


<h3 id="all-eyes-on-gileads-readout-of-remdesivir-for-covid-19">All Eyes on Gilead’s Readout of Remdesivir for COVID-19</h3>
<p><img src="https://www.biospace.com/getasset/4c1c4a41-23c9-4dc2-a44e-2738a2298a4f/;w=625;h=350" alt="img">
Michael Vi / Shutterstock</p>
<p>Gilead Sciences is expected to report data from a clinical trial of its antiviral drug remdesivir against COVID-19 soon. Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.</p>
<p>With a likely vaccine a year out, optimistically, the drug, which was originally developed to treat Ebola, is considered the closest hope for a treatment. It is involved in at least five clinical trials in the U.S. and China.</p>
<p>On April 4, the company announced it had accelerated production of the drug based on overwhelming demand. It currently has 1.5 million individual doses available, enough to treat 140,000 patients. More than 1,700 patients have been treated on an individual compassionate use basis to date.</p>
<p>Reading the tea leaves, analysts with Barclays think there is only a 20% chance that two of the clinical trials being run in China, one in mild-to-moderate cases and another in severely ill, will succeed. Barclays is more focused on what will happen to the company’s stock, even though at this time Gilead indicates it does not plan to charge for the drug. Barclays cites the drug’s complex manufacturing process, which normally takes a year to make, but has been streamlined to about six months, and the difficulties of setting a price and selling a drug for and during a global pandemic.</p>
<p>Barclays also expressed concern that the people being treated by the drug after the disease was well advanced, instead of at a point where it would be more effective.</p>
<p>Other analysts are studying what few moves the company is making publicly to make their predictions. For example, according to clinicaltrials.gov, the remdesivir trial page was updated, changing the size of a study in severe patients from 400 to 2,400, and the moderate patient trial from 600 to 1,600.</p>
<p>RBC believes these numbers include the compassionate use programs and writes, “It is unclear whether all of these patients will be considered in the primary endpoint, but any additional patients should help improve the powering to detect a potential treatment effect (though also indicates they believe more patients would be needed to be able to show a benefit).”</p>
<p>They go on to write, “We believe the changes improve alignment to the latest understanding of COVID-19’s course and should maximize sensitivity to detect any potential treatment effect, though they also imply that—perhaps based on data the company may be observing from ongoing experience with the drug—the magnitude of benefit, if any, is likely to be modest. This aligns with our view that remdesivir, like other COVID-19 drugs in development, would be more likely to have incremental effects in specific populations vs. proving to be a panacea.”</p>
<p>RBC suggests that Gilead’s decision to modify the trial, moving patients on ventilators to a different arm and changing the endpoints, moving to an improvement on a 7-point ordinal clinical assessment scale, means they may be looking for ways to identify if the drug is making more modest positive effects because more obvious ones may not have been possible in the previous design. “Overall, however, these endpoint modifications also underscore our view that based on evolving data to date, both published and followed internally by the company, Gilead may not be expecting to see dramatic benefits.”</p>
<p>Umer Raffat, an analyst at Evercore ISI, however, is more optimistic, writing in a note to investors that “since the Gilead-run trials are open label, the changes made were likely informed by emerging data from these trials. These trials now have LOTS more patients and different endpoints … but allow me to focus on key conclusions…”</p>
<p>The first conclusion of Raffat’s is that the likelihood of success in the moderate-patient trial has increased with the new endpoints, suggesting patients might be recovering more quickly, although it may not have a major impact on how quickly patients are discharged from the hospital, which was a previous primary endpoint, “but remdesivir likely did improve patient status while in hospital.”</p>
<p>The scope of the patients with severe disease has been expanded to include a higher severity level. Raffat interprets this to mean if researchers weren’t seeing any signals in this patient population, they wouldn’t be expanding the criteria to an even higher level. The earlier trial did not include patients on mechanical ventilation, but a “Part B’ has been added to include those patients.</p>
<p>Analysts, of course, are largely focusing on financial up- or downsides for the company. Most of the rest of the world is more interested in whether the drug works. We should get the first sense of that soon.


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>


<h3 id="武漢肺炎台防疫聯盟稱已能自製候選藥remdesivir-授權後可量產">武漢肺炎｜台防疫聯盟稱已能自製候選藥Remdesivir 授權後可量產</h3>
<p><img src="https://cdn.hk01.com/di/media/images/20200311/314385246944628736.jpeg/95nsi2F3omMPF5FXNZN6Q5RqXfDtJMCHnmQg5p5kIOY?v=w1280r16_9" alt="img">
新冠肺炎（COVID-19，俗稱武漢肺炎）疫情持續增溫，全球急需抗病毒藥物。台灣陽明大學、交通大學與台北榮民總醫院因應新冠肺炎疫情組成防疫聯盟，已與心悅生醫、台耀化學2家生技公司簽訂合作備忘錄，其中台耀化學評估具備自製瑞德西韋（Remdesivir）潛力，等待授權後即可量產。</p>
<p>榮陽交防疫聯盟陸續與台灣高端疫苗合作，協助申請快篩試劑與疫苗研發。聯盟目前期望結合陽明大學的生醫專長、交通大學的科法專長、以及台北榮總的臨床量能，協助台灣產業完成整備工作，因應疫情可能的威脅。</p>
<p>陽明大學、交通大學與台北榮民總醫院因應新冠肺炎疫情組成防疫聯盟，已與心悅生醫、台耀化學2家生技公司簽訂合作備忘錄，其中台耀化學評估具備自製瑞德西韋（Remdesivir）潛力。（榮陽交防疫聯盟）</p>
<p>榮陽交防疫聯盟表示，台耀化學是台灣原料藥大廠，也是台灣少數擁有超低溫設備的生藥公司，具有短時間內量產藥物的潛力。</p>
<p>台耀化學表示，大量合成瑞德西韋需要在攝氏-78℃的化學反應槽，由於一公斤的原料藥僅能供1000名病患的療程，台耀化學目前已與供應商確認瑞德西韋的原料供應鏈，可以在半個月內合成10公克、一個月內合成100公克，年產可達百公斤，提供大量病患療程所需的劑量。</p>
<p>台耀化學也已決定，一旦有防疫需求，可將現有產線轉投入大量生產瑞德西韋，預估每月可提供約2萬名病患的治療需求。</p>
<p>榮陽交防疫聯盟表示，雖然瑞德西韋還在臨床試驗階段，但仍是世界衛生組織認為是治療新冠肺炎的候選藥物之一。為了預防疫情持續擴散，台灣目前已有能力自製瑞德西韋，只要能取得授權，就算國際上因搶購缺貨，台灣也有能力保護民眾健康。</p>
<p>【相關圖輯】新冠肺炎｜酒精、漂白水用錯或有反效果！15個防疫不能犯的錯（點圖放大瀏覽）▼▼▼</p>
<ul>
<li>37 + 36 + 35</li>
</ul>
<p>【相關圖輯】新冠肺炎｜外傭亂溝漂白水？必讀4大漂白水需知（附菲律賓文及印尼文版本）↓↓↓</p>
<ul>
<li>10 + 9 + 8</li>
</ul>
<p>延伸閱讀：</p>
<p>國際新冠肺炎疫情嚴峻 歐洲8國、中東2國旅遊警示提升至二級</p>
<p>旅遊疫情警示升級 瑞士、挪威等8國提升至第二級</p>
<p>【本文獲「聯合新聞網」授權轉載。】


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>

						
						
						
                    </div>
                    
                    
                    <div class="after-post-tags">


		
                    
                    </div>
                    
                    




                </div>
                
            </div>
        </div>
        
        
    </div>


            </div>
<div class="jumbotron fortags">
	<div class="d-md-flex h-100">
		<div class="col-md-4 transpdark align-self-center text-center h-100">
			<div class="d-md-flex align-items-center justify-content-center h-100">
				<h2 class="d-md-block d-none align-self-center py-1 font-weight-light">Explore <span class="d-none d-md-inline">→</span></h2>
			</div>
		</div>


	</div>
</div>

<footer class="footer">
    <div class="container">
        <div class="row">
            <div class="col-md-6 col-sm-6 text-center text-lg-left">
               m donation charity &copy; Copyright 
            </div>
        </div>
    </div>
</footer>


        </div>


<script src="https://code.jquery.com/jquery-3.4.1.min.js"></script>
    
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.6/umd/popper.min.js" integrity="sha384-wHAiFfRlMFy6i5SRaxvfOCifBUQy1xHdJ/yoi7FRNXMRBu5WHdZYu1hA6ZOblgut" crossorigin="anonymous"></script>

<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js" integrity="sha384-JjSmVgyd0p3pXB1rRibZUAYoIIy6OrQ6VrjIEaFf/nJGzIxFDsf4x0xIM+B07jRM" crossorigin="anonymous"></script>

<script src="http://www.4stack.pro/js/mediumish.js"></script>


<script>
var userLang = navigator.language || navigator.userLanguage;

	$("#mymenu").append(' <li class="nav-item"><a class="nav-link" href="http://www.4stack.pro/series/pop-rumor">News</a></li>'); 
	$("#navbar_top").html(' <a href="http://www.4stack.pro/series/pop-rumor">More Rumors➜➜</a>');

</script>


<script type="application/javascript">
var doNotTrack = false;
if (!doNotTrack) {
	(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	})(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
	ga('create', 'UA-153100602-3', 'auto');
	
	ga('send', 'pageview');
}
</script>

    </body>
</html>
